A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/09/2004	US6814960 Prepared in a solid-phase synthesis using a trityl resin
11/09/2004	US6814958 Extract selected from the group of grape seed extract, a green tea extract, a blueberry extract and a silymarin extract; and at least one member selected from vitamin c and and vitamin e for treating periodontosis
11/09/2004	US6814955 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine.
11/09/2004	US6814954 Delivery of compounds for the treatment of Parkinsons through an inhalation route
11/09/2004	US6814953 Bronchodilating compositions and methods
11/09/2004	US6814929 Antibacterial composition for diffusing to combat bacteria contained in the air, a method of diffusing such a composition
11/09/2004	CA2317999C Pharmaceutical formulation of fluticasone propionate
11/09/2004	CA2282360C Preparation of powder agglomerates
11/09/2004	CA2280718C Administration of an injectable antibiotic in the ear of an animal
11/09/2004	CA2265824C Antifungal combination therapy
11/09/2004	CA2260750C Methods for providing safe local anesthesia
11/09/2004	CA2170047C Androstenone derivative
11/09/2004	CA2150546C Agent for inhibiting production of interleukin-8
11/09/2004	CA2144344C Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents
11/09/2004	CA2126195C Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
11/09/2004	CA2109572C Method for reducing side-effects of a drug
11/09/2004	CA2044853C Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker
11/04/2004	WO2004094655A2 Modulation of telomere-initiated cell signaling
11/04/2004	WO2004094652A2 Zinc-based screening test and kit for early diagnosis of prostate cancer
11/04/2004	WO2004094648A2 Methods of treating diseases responsive to induction of apoptosis and screening assays
11/04/2004	WO2004094647A2 Methods of treating diseases responsive to induction of apoptosis and screening assays
11/04/2004	WO2004094631A1 Di-glycosil glyceryl compounds for the stabilisation and preservation of biomaterials
11/04/2004	WO2004094599A2 Disease prevention and vaccination following thymic reactivation
11/04/2004	WO2004094595A2 MODIFIED iRNA AGENTS
11/04/2004	WO2004094468A2 Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
11/04/2004	WO2004094451A2 8&dollar;G(B)-VINYL-11&dollar;G(B)-(&dollar;G(V)-SUBSTITUTED)ALKYL-ESTRA-1,3,5(10)-TRIENES
11/04/2004	WO2004094446A1 Remedies for diseases caused by strengthened vascular smooth muscle using 14-membered ring macrolide compounds
11/04/2004	WO2004094432A1 Porphyrin compound containing biotinyl group and use thereof
11/04/2004	WO2004094429A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	WO2004094428A1 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo`2, 3d! pyrimidine hydrogen mesylate and its polymorphic forms
11/04/2004	WO2004094424A1 Nitrogen-containing heterocyclic compounds and use thereof
11/04/2004	WO2004094421A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	WO2004094418A1 Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
11/04/2004	WO2004094409A1 Novel ido inhibitors and methods of use
11/04/2004	WO2004094408A1 Substituted pyrimidinones and pyrimidinthiones as crf antagonists
11/04/2004	WO2004094407A1 Five-membered heterocyclic derivative
11/04/2004	WO2004094404A1 4-imidazolin-2-one compounds
11/04/2004	WO2004094402A1 NOVEL SUBSTANCE HAVING α-GLUCOSIDASE INHIBITING ACTIVITY AND FOOD CONTAINING THE SAME
11/04/2004	WO2004094391A2 Process for the preparation of valsartan and intermediates thereof
11/04/2004	WO2004094388A2 Indazole derivatives as jnk inhibitors
11/04/2004	WO2004094387A1 Alkylated iminodibenzyls as antioxidants
11/04/2004	WO2004094373A2 A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
11/04/2004	WO2004094372A2 Compounds useful as serine protease inhibitors
11/04/2004	WO2004094371A2 Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
11/04/2004	WO2004094370A2 Antibacterial pyrazole carboxylic acid hydrazides
11/04/2004	WO2004094369A2 Stabilized derivatives of ascorbic acid
11/04/2004	WO2004094020A2 Crystal growth devices and systems, and methods for using same
11/04/2004	WO2004093996A1 Topical sulfacetamide composition and method for treating seborrheic dermatitis
11/04/2004	WO2004093995A2 Use of antioxidants to treat bone loss disorders
11/04/2004	WO2004093918A2 Peg-wortmannin conjugates
11/04/2004	WO2004093917A2 Intranasal administration of triptans
11/04/2004	WO2004093916A1 A medicament for the two-step perioperative therapy of solid tumours
11/04/2004	WO2004093915A1 Pharmaceutical compositions for hepatitis c viral protease inhibitors
11/04/2004	WO2004093914A1 Formulations for treatment of pulmonary disorders comprising a bronchodilator, a vasoconstrictor and a corticosteroid
11/04/2004	WO2004093913A1 Treatment of hypertension
11/04/2004	WO2004093912A1 Preventive and/or therapeutic agent for neutrophil inflammation disease
11/04/2004	WO2004093911A1 Pharmaceutical composition for prostatic disease treatment
11/04/2004	WO2004093910A1 REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPARδ AGONIST
11/04/2004	WO2004093907A2 Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents
11/04/2004	WO2004093903A2 Methods and compositions for immunomodulation using cd1 antigens
11/04/2004	WO2004093896A1 Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
11/04/2004	WO2004093895A1 Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
11/04/2004	WO2004093891A1 Vegetable extract compositions comprising inodole acetic, methods for the preparation of said compsitions, and their use as cell growth inhibiting agents
11/04/2004	WO2004093888A1 Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses
11/04/2004	WO2004093887A1 Compositions comprising hyaluronic acid for the prevention of urogenital infections
11/04/2004	WO2004093886A1 Topical formulation of ivermectin for the treatment of dermatological conditions
11/04/2004	WO2004093885A1 Compositions containing lactulose for treating potavirus infections
11/04/2004	WO2004093884A2 High drug load mesalazine sachet
11/04/2004	WO2004093883A2 Sachet for a pharmaceutical composition
11/04/2004	WO2004093882A1 Remedies for diseases to be applied to eye
11/04/2004	WO2004093881A2 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
11/04/2004	WO2004093879A1 (3-{3-‘(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino!-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders
11/04/2004	WO2004093878A1 Use of fused pyridazine derivatives for treating dry eye disorders
11/04/2004	WO2004093877A1 Vitamin comprising pyroloquinoline quinone and use thereof
11/04/2004	WO2004093876A2 Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders
11/04/2004	WO2004093875A1 Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
11/04/2004	WO2004093874A1 Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy
11/04/2004	WO2004093873A1 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
11/04/2004	WO2004093871A1 Novel methods for the treatment of cancer
11/04/2004	WO2004093870A1 Treatment and prevention of otic disorders
11/04/2004	WO2004093869A1 Novel dietary compositions to reduce inflammation
11/04/2004	WO2004093868A1 Therapeutic combination of a cox-2 inhibitor and an aromatase inhibitor
11/04/2004	WO2004093867A2 Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
11/04/2004	WO2004093866A1 Process for preparing phenolic acid salts of gabapentin
11/04/2004	WO2004093865A1 Composition for slimming
11/04/2004	WO2004093864A1 Non-steroidal anti-inflammatory drug dosing regimen
11/04/2004	WO2004093863A1 A composition comprising an edible acid or its acidic salt and the use thereof
11/04/2004	WO2004093862A1 Pharmaceutical composition comprising edible acids or the acid salts and its use
11/04/2004	WO2004093861A1 Trospium containing compositions
11/04/2004	WO2004093860A1 Inhibitors of sars related coronavirus proteinase
11/04/2004	WO2004093858A1 Mmp expression inhibitor
11/04/2004	WO2004093857A1 Composition for relieving unpleasant symptoms accompanying change in protesterone
11/04/2004	WO2004093856A2 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia
11/04/2004	WO2004093854A2 Antineoplastic combinations
11/04/2004	WO2004093853A2 Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition
11/04/2004	WO2004093852A2 Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders
11/04/2004	WO2004093851A1 Alpha-hydroxy acid ester drug delivery compositions and methods of use
11/04/2004	WO2004093843A1 Delayed release tablet with defined core geometry
11/04/2004	WO2004093832A2 Cosmetic or pharmaceutical composition comprising a combination of at least one diacylglycerol and at least one fatty alcohol
11/04/2004	WO2004093828A2 Reverse-turn mimetics and method relating thereto

1 ... 4900 4901 4902 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 ... 7860